News
Cortado Ventures Doubleshot Newsletter: March 2024
Midcon VC Summit, Nuview, Ardley, and more.
Why We Invested: Cadenza Bio
Cortado Ventures invests in Cadenza Bio
Forbes: Cortado Ventures Recognized for Diversity Advocacy
We are proud to be recognized by Forbes.
Nuview: Nuview Acquires Astraea
Nuview acquires Astrea
Ardley: Launches Underwriting Engine
CEO and Founder of Ardley sits down for an exclusive interview
Cody Merrill: A Cortado Conversation with CorriXR Therapeutics CEO Deborah Moorad
CorriXR Therapeutics is the first spinout of ChristianaCare, a large Delaware-based healthcare system
Cortado Ventures Doubleshot Newsletter: February 2024
2023 Year in Review, Lumata Health, CorriXR and more.
CorriXR: OETA Feature
Our Principal, Susan Moring, joined CorriXR CEO, Deborah Moorad
Axios: Lumata Health hauls in $5.5M for virtual eye care
We are excited to share an exclusive feature published by Axios
Fortune: What do VCs really want from the Fed
This article discusses the impact of the Federal Reserve’s decision
Why We Invested: Lumata Health
Check out our latest “Why We Invested” blog
Nathaniel Harding: Year in Review and 2024 Outlook
Let’s look back at 2023 for VC and our firm to set the stage for an exciting 2024
Cortado Ventures Doubleshot Newsletter: January 2024
MidCon Markup, CorriXR, Nathaniel Harding, and more
Cortado Ventures Invests in CorriXR
Cortado Ventures Invests in CorriXR
Nathaniel Harding’s Ongoing Board Commitment
Nathaniel Harding renews commitment to OKC Chamber
CORTADO VENTURES